Head-to-head evidence
Lacosamide vs Phenytoin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Epilepsy
Shared mechanism: Voltage-gated sodium channels · full Epilepsy pipeline
Lacosamide
Marketed by UCB
NCT00136019 · Phase 3 · completed
Although the study was described as randomized and double-blind with an estimated 400 participants, the registry lists only the lacosamide intervention and no comparator arm. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Phenytoin
Marketed by Viatris and partners
NCT00210782 · Phase 3 · completed
The study was a randomized, double-blind comparison of topiramate and phenytoin involving 262 participants, using the clinical endpoint of time to first seizure. Because the registry does not report whether the primary comparison was statistically significant, the trial provides a well-designed but currently inconclusive evidence base.
Next expected readout: December 2026 · NCT05637086 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lacosamide's landscape · Phenytoin's landscape